Azienda Unita' Sanitaria Locale Toscana Nord Ovest — Clinical Trial Site

83 Registered trials

40 Currently recruiting

Organisation

Azienda Unita' Sanitaria Locale Toscana Nord Ovest

Location

Leghorn, Italy

Identifier

ORG-100045219

Address

Viale Vittorio Alfieri 36, 57124, Italy

Departments

-
039001: Dipartimento Oncologico
039101: Dipartimento Oncologico
6202: U.O.C. Oncologia Medica
Cardiologia
D.H. Oncologia
Department of Neurosurgery
Department of oncology
Dipartimento di Oncologia
Dipartimento di Oncologia ASL 2
Dipartimento Oncologico
Dipartimento Oncologico - SC Oncologia
Dipartimento Oncologico - SC Oncologia Medica Livorno
Divisione di Oncologia
Divisione Oncologica
Ematologia - Ospedale di Livorno
Emergency
Endoscopia Digestiva
IT10014:NA
Materno Infantile
Medical Oncology
N/A
Neurochirurgia
Neurology
Oncologia
Oncologia Medica
Oncology
Oncology Department
Oncology Division
Oncology Unit
Ospedale Civile di Livorno - UOC Oncologia Medica
Ospedale San Luca, Divisione di Oncologia
Pneumologia
SC Oncologia
U.O. Aziendale di Endocrinologia
U.O. di Oncologia
U.O. di Oncologia Medica
U.O. Oncologia Medica
U.O.C. Medical Oncology
U.O.C. Neurologia, Ospedale Apuane, Massa
U.O.C. Oncologia
U.O.C. Oncologia Medica
U.O.C. Oncologia Medica Livorno
UOC di Oncologia Medica
UOC Neonatologia e Pediatria
UOC Oncologia Medica
UOC Oncologia Medica - Ospedale San Luca
UOC Oncologia Medica – Ospedale Civile Livorno
UOC Oncologia Medica di Livorno
UOC Oncologia Medica Livorno
UOC Oncologia Medica Livorno VDE-AVC
UOC Ostetricia e Ginecologia

Clinical trials at this site (83)

Search interface

A Study to Learn About the Study Medicine Called PF-07248144 in Combination with Fulvestrant in People with HR-positive, HER2-negative Advan… Recruiting

2025-520566-22-00 Hormone Receptor-Positive, HER2-Negative Advanced/Metas 5 2025-11-10
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin i… Recruiting

2024-518365-10-00 Previously Untreated Advanced or Metastatic Non-Squamou 5 2025-10-28
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-line Treatment of PD-L1-high Metastatic Non-small Cell Lung… Recruiting

2024-517780-24-00 Lung Cancer 5 2025-09-18
ENGIC 01 - COLOSOTO: A single-arm phase II study evaluating 5-fluorouracil plus Panitumumab (anti-EGFR) and Sotorasib (KRAS G12C inhibitor) … Recruiting

2024-514030-20-00 colorectal cancer 4 2025-08-29
Study of Sacituzumab Govitecan Versus Standard of Care in Participants with Previously Treated Extensive Stage Small Cell Lung Cancer Recruiting

2024-515884-69-00 Extensive Stage Small Cell Lung Cancer (ES-SCLC) 5 2025-07-16
A Study to Assess safety and Effectiveness of the Inavolisib Plus a CDK4/6 Inhibitor and Letrozole Versus Placebo Plus a CDK4/6 Inhibitor an… Recruiting

2024-516162-11-00 Endocrine-Sensitive phosphatidylinositol 3-kinase (PIK3 5 2025-07-14
Safety, efficacy, and pharmacokinetics of BNT327 in combination with chemotherapy and other investigational agents for lung cancer Recruiting

2024-515764-31-00 Non-small cell lung cancer 10 2025-06-13
Elacestrant versus Standard Endocrine Therapy in Women and Men with Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast C… Recruiting

2024-515445-42-00 Node-positive, Estrogen Receptor-positive, HER2-negativ 5 2025-03-24
Continued PD-L1 inhibition with atezolizumab with rechallenge chemotherapy in patients with sensitive relapse SCLC progressing on first-line… Recruiting

2024-511945-20-00 patients affected by small cell lung cancer (SCLC) 4 2025-01-24
MK-1084 with Pembrolizumab in 1L Locally Advanced or Metastatic NSCLC With KRAS G12C Mutations and PD-L1 ≥50% Recruiting

2023-507776-42-00 Non-small cell lung cancer 5 2024-11-14
A phase 3 trial comparing a therapeutic cancer vaccine OSE2101 to chemotherapy docetaxel in patients with metastatic Non-Small Cell Lung Can… Recruiting

2023-509340-10-00 Patients with HLA-A2 positive phenotype and metastatic 5 2024-10-29
PHASE III RANDOMIZED STUDY OF FOLFOXIRI PLUS BEVACIZUMAB AND ATEZOLIZUMAB VERSUS FOLFOXIRI PLUS BEVACIZUMAB AS FIRST-LINE TREATMENT OF UNRES… Recruiting

2023-506632-32-00 Metastatic colorectal cancer 5 2024-10-28
Regorafenib for recurrent meningioma. A multicenter, randomized phase II study (MIRAGE trial) Recruiting

2024-510954-28-01 grade 1, 2 and 3 meningioma 4 2024-09-23
HARMONi-3 Recruiting

2024-513087-26-00 Metastatic Non-small Cell Lung Cancer 5 2024-09-10
Registry-based randomized trial to determine the role of Oxygen in acute Pulmonary Embolism Recruiting

2024-511959-18-01 Acute Pulmonary Embolism 5 2024-07-01
A multicenter single-arm phase II interventional study to evaluate the activity and safety of the combination of Platinum-Pemetrexed based c… Recruiting

2023-506714-43-00 ALK positive Non-Small Cell Lung Cancer 4 2024-03-15
Tranexamic acid for hyperacute spontaneous IntraCerebral Haemorrhage (TICH-3) Recruiting

2022-500587-35-01 Stroke 5 2023-07-06
Efficacy of PErioperative PEmbrolizumab treatment in patients with resectable metastases from kidney cancer. The PE-PE study Ended

2024-512180-31-00 Oligometastatic renal cell carcinoma 4 2025-03-14
Potential protective role of SGLT-2 inhibitors for chemotherapy-induced cardiotoxicity (PROTECT trial) Ended

2024-518611-18-00 Chemotherapy-induced cardiotoxicity in breast cancer 4 2024-12-03
Transmural Healing and Disease Modifying Effect of Guselkumab in Crohn’s Disease Patients Ended

2023-504040-34-01 Crohn’s Disease 5 2024-11-12
A clinical study of MK-7240 for the treatment of Crohn’s disease (MK-7240-008) Ended

2023-508636-61-00 Crohn’s Disease 5 2024-10-24
A Study Evaluating Pharmacokinetic similarity between ABP 234 and Keytruda® (pembrolizumab) in Subjects with Early-stage Non-squamous Non-sm… Ended

2023-508359-38-00 Early-stage Non-squamous Non-small Cell Lung Cancer 5 2024-06-05
A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab Injections Before and After Surgery for the Treatment of Adult Patients wit… Ended

2023-505928-59-00 Triple Negative or Hormone Receptor low/HER2-negative B 5 2024-04-15
A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination with Pembrolizumab, TransCon TLR7/8 Agonist, or … Ended

2023-509143-27-00 Locally advanced or metastatic solid tumor malignancies 7 2023-11-27